For the Inventor, By the Inventor

Enter assignee name

Oss, Netherlands

Synaffix B.v.

USPTO Granted Patents = 31

% Expired Patents = 3.2

EPO Patents = 17

Trademarks = 2

Forward Citations = 321

Loading Chart...

Loading Chart...

16 inventors (with patents filed for the assignee):

Floris Louis Van Delft (31 out of 32 patents)

Maria Antonia Wijdeven (21 out of 21 patents)

Sander Sebastiaan Van Berkel (17 out of 17 patents)

4. Remon Van Geel (14 out of 14 patents)

5. Jorge Merijn Mathieu Verkade (12 out of 13 patents)

6. Frederik Jan Dommerholt (7 out of 7 patents)

7. Petrus Josephus Jacobus Maria Van De Sande (7 out of 7 patents)

8. Ryan Heesbeen (6 out of 6 patents)

9. Floris Petrus Johannes Theodorus Rutjes (5 out of 6 patents)

10. Inge Catharina Josephina Hurkmans (4 out of 4 patents)

11. Jorin Hoogenboom (3 out of 4 patents)

12. Brian Maria Gerardus Janssen (2 out of 2 patents)

13. Anna Agnieszka Wasiel (1 out of 1 patent)

14. Maria Antonia Van Berkel (1 out of 2 patents)

15. Remon Gvan Eel (1 out of 1 patent)

Core Competencies:

Enediyne Conjugates

Antibody-Conjugates

Sulfamide Linkers

Glycoprotein Modification

Metal-Free Click Reactions

Therapeutic Index

Bioconjugates

Glycosyltransferase

Cycloaddition

Heteroaryl Compounds

Trimming Enzymes

Modified Antibodies

31 patents: Sort by Forward Citations

1. 12642861 - Enediyne conjugates (2026-06-02),

2. 12440573 - Antibody-conjugates for targeting of tumours expressing PTK7 (2025-10-14),

3. 12397063 - Antibody-conjugates for targeting of tumours expressing Trop-2 (2025-08-26),

4. 12281135 - Synthesis of 6-azido-6-deoxy-2-n-acetyl-hexosamine-nucleoside diphosphate (2025-04-21),

5. 12194107 - Modified antibody, antibody-conjugate and process for the preparation thereof (2025-01-14),

6. 12180145 - Fused cyclooctyne compounds and their use in metal-free click reactions (2024-12-31),

7. 12084448 - Process for the cycloaddition of a (hetero)aryl 1,3-dipole compound with a (hetero)cycloalkyne (2024-09-10),

8. 12049656 - Process for the modification of a glycoprotein using a glycosyltransferase that is or is derived from a β(1,4)-n-acetylgalactosaminyltransferase (2024-07-30),

9. 11957763 - Sulfamide linkers for use in bioconjugates (2024-04-16),

10. 11951175 - Bioconjugates containing sulfamide linkers for use in treatment (2024-04-09),

11. 11850286 - Sulfamide linker, conjugates thereof, and methods of preparation (2023-12-26),

12. 11713453 - Enzymes for trimming of glycoproteins (2023-08-01),

13. 11590239 - Antibody-conjugates with improved therapeutic index for targeting CD30 tumours and method for improving therapeutic index of antibody-conjugates (2023-02-28),

14. 11358921 - Fused cyclooctyne compounds and their use in metal-free click reactions (2022-06-14),

15. 11338043 - Antibody-conjugates with improved therapeutic index for targeting HER2 tumours and method for improving therapeutic index of antibody-conjugates (2022-05-24),

Synaffix B.V., based in Oss, Netherlands, specializes in the development of innovative antibody-drug conjugate (ADC) technologies. The company focuses on enhancing the efficacy and safety of cancer therapies through its proprietary platforms, which enable the design and production of highly targeted treatments. By leveraging advanced bioconjugation techniques, Synaffix aims to improve therapeutic outcomes for patients while minimizing side effects, positioning itself as a key player in the biopharmaceutical sector dedicated to oncology advancements.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

31 Patents

#2 in Oss

#245 in Netherlands

#21,217 in the World

Oss, Netherlands

Synaffix B.v.

Forward Citations = 321

16 inventors:

Floris Louis Van Delft (31 out of 32 patents)

Maria Antonia Wijdeven (21 out of 21 patents)

Sander Sebastiaan Van Berkel (17 out of 17 patents)

4. Remon Van Geel (14 out of 14 patents)

5. Jorge Merijn Mathieu Verkade (12 out of 13 patents)

Please report any incorrect information to [email protected]

Loading…